Home・Stock List・Roivant Sciences Ltd

Roivant Sciences Ltd

Closed

SectorHealthcare

34.58 0.26

Buy Sell

Overview

Share price change

24h

Current

Min

34.24

Max

35.5

Key metrics
By Trading Economics
Income	669M 356M
Sales	521K 2.5M
Profit margin	14,116.825
Employees	721
EBITDA	744M 455M

Recommendations
By TipRanks
Recommendations	Strong Buy
12 Months Forecast	+5.84% upside

Market Stats
By TradingEconomics
Market Cap	3.9B 24B
Previous open	34.32
Previous close	34.58

News Sentiment

By Acuity

50%

175 / 340 Healthcare

Roivant Sciences Ltd Chart

Past performance is not a reliable indicator of future results.

Related News

4 Aug 2026, 20:02 UTC

Roivant Sciences is rising amid positive market sentiment and declining crude oil prices. Remarks from Treasury Secretary Scott Bessent also support the favorable environment.

3 Aug 2026, 20:06 UTC

Roivant Sciences Ltd shares are declining today, breaking a trend of higher closes. Broader market indices are up, but no specific news explains the drop.

31 Jul 2026, 20:02 UTC

Roivant Sciences Ltd shares are lower today amid significant declines in biotechnology stocks, breaking a trend of higher daily closes since Thursday.

30 Jul 2026, 23:46 UTC

Roivant Sciences Ltd shares are higher in after-market trading, reflecting a modest gain since Thursday's close. The stock fluctuated within a narrow range.

29 Jul 2026, 23:02 UTC

Roivant Sciences Ltd shares are lower in after-market hours amid broader market concerns and unusual volatility, with no specific company news identified.

28 Jul 2026, 23:06 UTC

Roivant Sciences Ltd shares are lower in after-market hours, continuing a trend of declines over the past three sessions without any specific news to explain the movement.

24 Jul 2026, 18:46 UTC

Roivant Sciences Ltd shares are trading higher, reflecting broader market dynamics amid a rebound in some sectors following a significant decline in oil prices.

23 Jul 2026, 20:06 UTC

Roivant Sciences Ltd is higher during Thursday's session, despite pulling back from an earlier session high. No specific news was identified for the movement.

22 Jul 2026, 22:26 UTC

Roivant Sciences Ltd shares are lower in after-market trading, with no specific news identified to explain the decline amid broader market volatility.

21 Jul 2026, 22:21 UTC

Roivant Sciences Ltd shares are lower in after-market hours, despite a broader market rebound following positive earnings from companies like General Motors and 3M.

20 Jul 2026, 16:36 UTC

Roivant Sciences Ltd. shares are lower today amid ongoing Middle East conflict affecting market sentiment and fluctuations in Brent crude prices.

Peer Comparison

Price change

Roivant Sciences Ltd Forecast

Price Target

By TipRanks

5.84% upside

12 Months Forecast

Average 36.61 USD 5.84%

High 42 USD

Low 29.29 USD

Based on 7 Wall Street analysts offering 12 month price targets forRoivant Sciences Ltd - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

7 ratings

Buy

Hold

Sell

Based on 7 analysts giving stock ratings to Roivant Sciences Ltd - Dist in the past 3 months.

Sentiment

By Acuity

175 / 340 Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Roivant Sciences Ltd

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups. It offers VTAMA, a novel topical approved for the treatment of psoriasis and in development for the treatment of atopic dermatitis; IMVT-1402 and batoclimab, which are fully human monoclonal antibodies that targets the neonatal Fc receptor in development across various IgG-mediated autoimmune indications; brepocitinib, a potent small molecule inhibitor of TYK2 and JAK1 in development for the treatment of dermatomyositis and non-infectious uveitis, as well as for other therapies in various stages of clinical development; and Namilumab, a fully human anti-GM-CSF monoclonal antibody under Phase 2 clinical trial for the treatment of inflammatory and autoimmune diseases. The company also provides delivery platforms comprising lipid nanoparticle platform and ligand conjugate platform. It has collaboration and license agreements with Boehringer Ingelheim International, GmbH for conducting discovery work on RNA-specific adenosine deaminase 1 targeting and modulating compounds; and with Japan Tobacco Inc. for the rights to develop, register, and market tapinarof in Japan for the treatment of psoriasis and atopic dermatitis. The company was founded in 2014 and is based in London, the United Kingdom.